Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday

Syros Pharmaceuticals (NASDAQ:SYRS) is projected to announce its earnings results before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.05 on Tuesday. The company has a 50 day moving average price of $0.16 and a 200-day moving average price of $0.83. Syros Pharmaceuticals has a 1-year low of $0.03 and a 1-year high of $6.93. The firm has a market cap of $1.23 million, a price-to-earnings ratio of -0.02 and a beta of 1.31.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Syros Pharmaceuticals in a report on Friday. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.